Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC vs FAC in High Risk Node-Negative Breast Cancer
NCT00121992Phase 3Completed
- Sponsor
- GEICAM
- Start
- Jul 1999
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Disease-free Survival at 10 years. Started Jul 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00121992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121992.